Opinion on Immunology and Inflammation

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Wyeth: Enbrel inflames profits

Wyeth has reported positive second quarter earnings, thanks in part to strong demand for the arthritis treatment Enbrel. With its launch in Japan already boosting sales, even with a drop in the drug's hard-sell marketing post-Vioxx, it is expected to remain well-positioned to carry the fight to Centocor's competing Remicade.

Published By Datamonitor
21 Jul 2005
CommentWire
CommentWire

World COPD Day: a good start but greater awareness needed

The fourth World COPD Day will raise awareness about chronic obstructive pulmonary disease (COPD), a fatal but little-known and thus under-diagnosed disease. While lack of awareness among both the general public and physicians remains a challenge to fighting the disease, events such as this are essential. However, more needs to be done to effectively counteract the problem of under-diagnosis.

Published By Datamonitor
16 Nov 2005
Expert View
Expert View

World Congress on Osteoporosis highlights changing face of bone health

Datamonitor attended this year's International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis, the most important meeting on the osteoporosis calendar. A number of major pharmaceutical firms had a presence at the meeting, indicating the significance of this market.

Published By Datamonitor
18 May 2010
ResearchWire
ResearchWire

Vaccines: sales show global growth

Published By Datamonitor
17 Mar 2006
ResearchWire
ResearchWire

Upper GI disorders: prevalence in the seven major markets

Published By Datamonitor
10 Aug 2007
CommentWire
CommentWire

Ulcerative colitis: saliva peptide shows promise

Researchers have found that epidermal growth factor (EGF), a substance produced naturally in saliva, is a well tolerated and simple treatment that can result in a rapid improvement of ulcerative colitis symptoms. If future trials are successful, EGF may be able to fill a market gap for patients who have not benefited from standard therapies.

Published By Datamonitor
28 Jul 2003
CommentWire
CommentWire

Ulcer drugs: challenges in store

Procter & Gamble's [PG] launch of Prilosec OTC will have wide-ranging effects on the market for heartburn and ulcer drugs. The availability of an OTC alternative is leading US insurance companies to restrict access to competing prescription drugs. Although generic OTC omeprazole will not be available for several years, PPI companies must find successor products to protect their franchises.

Published By Datamonitor
22 Sep 2003
Expert View
Expert View

UK recommendation for Merck's Simponi but it may struggle to make an impact

The National Institute for Health and Clinical Excellence has recommended Simponi for psoriatic arthritis. Based on this, Datamonitor believes that the drug will gain further positive recommendations in other rheumatology indications. However, while Simponi does have dosing advantages over other approved biologics, it is unlikely to make a huge impact on the UK market.

Published By Datamonitor
18 Mar 2011
Expert View
Expert View

UK Arthritis Sufferers Receiving Second Best in Pain Medication

Many rheumatoid and osteoarthritis sufferers in the UK may have to settle for second best in pain medication and are being put at risk of developing serious gastrointestinal side effects (GI) according to market analysts, Datamonitor.

Published By Datamonitor
20 Feb 2002
CommentWire
CommentWire

UCB: innovative payment scheme behind Cimzia approval sets precedent in rheumatology

UCB's new rheumatoid arthritis drug, Cimzia, has been recommended for use on the NHS but only in conjunction with a company-sponsored patient access scheme. As such, UCB will cover all treatment costs for the first 12 weeks of therapy. This is a shrewd way of ensuring Cimzia's use by the cost-conscious NHS, and could herald change in both prescribing practices and future NICE submissions.

Published By Datamonitor
26 Jan 2010

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.